J&J reports strong survival gains with Tecvayli-Talvey regimen in myeloma

24 July 2026

US pharma major Johnson & Johnson (NYSE: JNJ) has reported positive top-line Phase III data showing that a dual bispecific antibody regimen sharply improved survival outcomes in patients with relapsed or refractory multiple myeloma.

The global, three-arm MonumenTAL-6 trial evaluated Tecvayli (teclistamab-cqyv), a BCMA-targeting bispecific antibody, plus Talvey (talquetamab-tgvs), which targets GPRC5D, as well as Talvey plus pomalidomide, in patients who had received one to four prior lines of therapy, including an anti-CD38 antibody and lenalidomide.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK